SuperworthCRISPR Therapeutics EV/EBIT CRSP
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 13.9×
- Aug 2022
- 7-year median
- 11.8×
- 7-year range
- 4.1× to 222×
- Peer median
- 17.8×
CRISPR Therapeutics has no meaningful EV/EBIT today: it made an operating loss of $534.3M over the last twelve months.
It was last meaningful in Aug 2022, at 13.9×.
On the days it had one over the last 7 years, its median was 11.8×, from 4.1× in May 2022 to 222× in Jul 2020.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2022 | 13.9× | 4.1× | 14.3× |
| 2021 | 8.6× | 7.5× | 17.9× |
| 2020 | 217× | 29.9× | 222× |
Against its peers
Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| CRSPCRISPR Therapeutics | n/m |
| KRYSKrystal Biotech | 42.4× |
| ADMAAdma Biologics | 10.9× |
| RGENRepligen | 160× |
| VCELVericel | 116× |
| TECHBIO-TECHNE | 44.9× |
| HALOHalozyme Therapeutics | 17.4× |
| NBIXNeurocrine Biosciences | 18.2× |
| EXELExelixis | 15.4× |
| INCYIncyte | 10.1× |
| UTHRUnited Therapeutics | 16.1× |
| Peer median | 17.8× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on CRISPR Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.